Table of Contents Chapter 1 Overview of Metabolic Disorders Drugs 1.1 Definition of Metabolic Disorders Drugs in This Report 1.2 Commercial Types of Metabolic Disorders Drugs 1.2.1 Tablet 1.2.2 Injection 1.3 Downstream Application of Metabolic Disorders Drugs 1.3.1 Diabetes 1.3.2 Disorders of the Thyroid and Pituitary Gland 1.3.3 Other 1.4 Development History of Metabolic Disorders Drugs 1.5 Market Status and Trend of Metabolic Disorders Drugs 2013-2023 1.5.1 Global Metabolic Disorders Drugs Market Status and Trend 2013-2023 1.5.2 Regional Metabolic Disorders Drugs Market Status and Trend 2013-2023 Chapter 2 Global Market Status and Forecast by Regions 2.1 Market Development of Metabolic Disorders Drugs 2013-2017 2.2 Sales Market of Metabolic Disorders Drugs by Regions 2.2.1 Sales Volume of Metabolic Disorders Drugs by Regions 2.2.2 Sales Value of Metabolic Disorders Drugs by Regions 2.3 Production Market of Metabolic Disorders Drugs by Regions 2.4 Global Market Forecast of Metabolic Disorders Drugs 2018-2023 2.4.1 Global Market Forecast of Metabolic Disorders Drugs 2018-2023 2.4.2 Market Forecast of Metabolic Disorders Drugs by Regions 2018-2023 Chapter 3 Global Market Status and Forecast by Types 3.1 Sales Volume of Metabolic Disorders Drugs by Types 3.2 Sales Value of Metabolic Disorders Drugs by Types 3.3 Market Forecast of Metabolic Disorders Drugs by Types Chapter 4 Global Market Status and Forecast by Downstream Industry 4.1 Global Sales Volume of Metabolic Disorders Drugs by Downstream Industry 4.2 Global Market Forecast of Metabolic Disorders Drugs by Downstream Industry Chapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry 5.1 North America Metabolic Disorders Drugs Market Status by Countries 5.1.1 North America Metabolic Disorders Drugs Sales by Countries (2013-2017) 5.1.2 North America Metabolic Disorders Drugs Revenue by Countries (2013-2017) 5.1.3 United States Metabolic Disorders Drugs Market Status (2013-2017) 5.1.4 Canada Metabolic Disorders Drugs Market Status (2013-2017) 5.1.5 Mexico Metabolic Disorders Drugs Market Status (2013-2017) 5.2 North America Metabolic Disorders Drugs Market Status by Manufacturers 5.3 North America Metabolic Disorders Drugs Market Status by Type (2013-2017) 5.3.1 North America Metabolic Disorders Drugs Sales by Type (2013-2017) 5.3.2 North America Metabolic Disorders Drugs Revenue by Type (2013-2017) 5.4 North America Metabolic Disorders Drugs Market Status by Downstream Industry (2013-2017) Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry 6.1 Europe Metabolic Disorders Drugs Market Status by Countries 6.1.1 Europe Metabolic Disorders Drugs Sales by Countries (2013-2017) 6.1.2 Europe Metabolic Disorders Drugs Revenue by Countries (2013-2017) 6.1.3 Germany Metabolic Disorders Drugs Market Status (2013-2017) 6.1.4 UK Metabolic Disorders Drugs Market Status (2013-2017) 6.1.5 France Metabolic Disorders Drugs Market Status (2013-2017) 6.1.6 Italy Metabolic Disorders Drugs Market Status (2013-2017) 6.1.7 Russia Metabolic Disorders Drugs Market Status (2013-2017) 6.1.8 Spain Metabolic Disorders Drugs Market Status (2013-2017) 6.1.9 Benelux Metabolic Disorders Drugs Market Status (2013-2017) 6.2 Europe Metabolic Disorders Drugs Market Status by Manufacturers 6.3 Europe Metabolic Disorders Drugs Market Status by Type (2013-2017) 6.3.1 Europe Metabolic Disorders Drugs Sales by Type (2013-2017) 6.3.2 Europe Metabolic Disorders Drugs Revenue by Type (2013-2017) 6.4 Europe Metabolic Disorders Drugs Market Status by Downstream Industry (2013-2017) Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry 7.1 Asia Pacific Metabolic Disorders Drugs Market Status by Countries 7.1.1 Asia Pacific Metabolic Disorders Drugs Sales by Countries (2013-2017) 7.1.2 Asia Pacific Metabolic Disorders Drugs Revenue by Countries (2013-2017) 7.1.3 China Metabolic Disorders Drugs Market Status (2013-2017) 7.1.4 Japan Metabolic Disorders Drugs Market Status (2013-2017) 7.1.5 India Metabolic Disorders Drugs Market Status (2013-2017) 7.1.6 Southeast Asia Metabolic Disorders Drugs Market Status (2013-2017) 7.1.7 Australia Metabolic Disorders Drugs Market Status (2013-2017) 7.2 Asia Pacific Metabolic Disorders Drugs Market Status by Manufacturers 7.3 Asia Pacific Metabolic Disorders Drugs Market Status by Type (2013-2017) 7.3.1 Asia Pacific Metabolic Disorders Drugs Sales by Type (2013-2017) 7.3.2 Asia Pacific Metabolic Disorders Drugs Revenue by Type (2013-2017) 7.4 Asia Pacific Metabolic Disorders Drugs Market Status by Downstream Industry (2013-2017) Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry 8.1 Latin America Metabolic Disorders Drugs Market Status by Countries 8.1.1 Latin America Metabolic Disorders Drugs Sales by Countries (2013-2017) 8.1.2 Latin America Metabolic Disorders Drugs Revenue by Countries (2013-2017) 8.1.3 Brazil Metabolic Disorders Drugs Market Status (2013-2017) 8.1.4 Argentina Metabolic Disorders Drugs Market Status (2013-2017) 8.1.5 Colombia Metabolic Disorders Drugs Market Status (2013-2017) 8.2 Latin America Metabolic Disorders Drugs Market Status by Manufacturers 8.3 Latin America Metabolic Disorders Drugs Market Status by Type (2013-2017) 8.3.1 Latin America Metabolic Disorders Drugs Sales by Type (2013-2017) 8.3.2 Latin America Metabolic Disorders Drugs Revenue by Type (2013-2017) 8.4 Latin America Metabolic Disorders Drugs Market Status by Downstream Industry (2013-2017) Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry 9.1 Middle East and Africa Metabolic Disorders Drugs Market Status by Countries 9.1.1 Middle East and Africa Metabolic Disorders Drugs Sales by Countries (2013-2017) 9.1.2 Middle East and Africa Metabolic Disorders Drugs Revenue by Countries (2013-2017) 9.1.3 Middle East Metabolic Disorders Drugs Market Status (2013-2017) 9.1.4 Africa Metabolic Disorders Drugs Market Status (2013-2017) 9.2 Middle East and Africa Metabolic Disorders Drugs Market Status by Manufacturers 9.3 Middle East and Africa Metabolic Disorders Drugs Market Status by Type (2013-2017) 9.3.1 Middle East and Africa Metabolic Disorders Drugs Sales by Type (2013-2017) 9.3.2 Middle East and Africa Metabolic Disorders Drugs Revenue by Type (2013-2017) 9.4 Middle East and Africa Metabolic Disorders Drugs Market Status by Downstream Industry (2013-2017) Chapter 10 Market Driving Factor Analysis of Metabolic Disorders Drugs 10.1 Global Economy Situation and Trend Overview 10.2 Metabolic Disorders Drugs Downstream Industry Situation and Trend Overview Chapter 11 Metabolic Disorders Drugs Market Competition Status by Major Manufacturers 11.1 Production Volume of Metabolic Disorders Drugs by Major Manufacturers 11.2 Production Value of Metabolic Disorders Drugs by Major Manufacturers 11.3 Basic Information of Metabolic Disorders Drugs by Major Manufacturers 11.3.1 Headquarters Location and Established Time of Metabolic Disorders Drugs Major Manufacturer 11.3.2 Employees and Revenue Level of Metabolic Disorders Drugs Major Manufacturer 11.4 Market Competition News and Trend 11.4.1 Merger, Consolidation or Acquisition News 11.4.2 Investment or Disinvestment News 11.4.3 New Product Development and Launch Chapter 12 Metabolic Disorders Drugs Major Manufacturers Introduction and Market Data 12.1 Zealand Pharma 12.1.1 Company profile 12.1.2 Representative Metabolic Disorders Drugs Product 12.1.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Zealand Pharma 12.2 Rhythm 12.2.1 Company profile 12.2.2 Representative Metabolic Disorders Drugs Product 12.2.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Rhythm 12.3 OxThera 12.3.1 Company profile 12.3.2 Representative Metabolic Disorders Drugs Product 12.3.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of OxThera 12.4 Biophytis 12.4.1 Company profile 12.4.2 Representative Metabolic Disorders Drugs Product 12.4.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Biophytis 12.5 Biophytis 12.5.1 Company profile 12.5.2 Representative Metabolic Disorders Drugs Product 12.5.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Biophytis 12.6 Zafgen 12.6.1 Company profile 12.6.2 Representative Metabolic Disorders Drugs Product 12.6.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Zafgen 12.7 PerkinElmer 12.7.1 Company profile 12.7.2 Representative Metabolic Disorders Drugs Product 12.7.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of PerkinElmer 12.8 Eternygen 12.8.1 Company profile 12.8.2 Representative Metabolic Disorders Drugs Product 12.8.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Eternygen 12.9 Pronutria Biosciences 12.9.1 Company profile 12.9.2 Representative Metabolic Disorders Drugs Product 12.9.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Pronutria Biosciences 12.10 MedGenome 12.10.1 Company profile 12.10.2 Representative Metabolic Disorders Drugs Product 12.10.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of MedGenome 12.11 CellCentric 12.11.1 Company profile 12.11.2 Representative Metabolic Disorders Drugs Product 12.11.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of CellCentric 12.12 Nimbus Therapeutics 12.12.1 Company profile 12.12.2 Representative Metabolic Disorders Drugs Product 12.12.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Nimbus Therapeutics 12.13 Mitobridge 12.13.1 Company profile 12.13.2 Representative Metabolic Disorders Drugs Product 12.13.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Mitobridge 12.14 Exelixis, Inc. 12.14.1 Company profile 12.14.2 Representative Metabolic Disorders Drugs Product 12.14.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Exelixis, Inc. 12.15 Outpost Medicine 12.15.1 Company profile 12.15.2 Representative Metabolic Disorders Drugs Product 12.15.3 Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Outpost Medicine 12.16 Anchor Therapeutics 12.17 Verva Pharmaceuticals Chapter 13 Upstream and Downstream Market Analysis of Metabolic Disorders Drugs 13.1 Industry Chain of Metabolic Disorders Drugs 13.2 Upstream Market and Representative Companies Analysis 13.3 Downstream Market and Representative Companies Analysis Chapter 14 Cost and Gross Margin Analysis of Metabolic Disorders Drugs 14.1 Cost Structure Analysis of Metabolic Disorders Drugs 14.2 Raw Materials Cost Analysis of Metabolic Disorders Drugs 14.3 Labor Cost Analysis of Metabolic Disorders Drugs 14.4 Manufacturing Expenses Analysis of Metabolic Disorders Drugs Chapter 15 Report Conclusion Chapter 16 Research Methodology and Reference 16.1 Methodology/Research Approach 16.1.1 Research Programs/Design 16.1.2 Market Size Estimation 16.1.3 Market Breakdown and Data Triangulation 16.2 Data Source 16.2.1 Secondary Sources 16.2.2 Primary Sources 16.3 Reference

List of Tables Table Advantage and Disadvantage of Tablet Table Advantage and Disadvantage of Injection Table Sales Volume of Metabolic Disorders Drugs by Regions 2013-2017 Table Sales Value of Metabolic Disorders Drugs by Regions 2013-2017 Table Production Volume of Metabolic Disorders Drugs by Regions 2013-2017 Table Global Sales Volume of Metabolic Disorders Drugs by Regions 2018-2023 Table Global Sales Value of Metabolic Disorders Drugs by Regions 2018-2023 Table Global Production Volume of Metabolic Disorders Drugs by Regions 2018-2023 Table Sales Volume of Metabolic Disorders Drugs by Types 2013-2017 Table Sales Value of Metabolic Disorders Drugs by Types 2013-2017 Table Sales Volume Forecast of Metabolic Disorders Drugs by Types 2018-2023 Table Sales Value Forecast of Metabolic Disorders Drugs by Types 2018-2023 Table Sales Volume of Metabolic Disorders Drugs by Downstream Industry 2013-2017 Table Sales Volume Forecast of Metabolic Disorders Drugs by Downstream Industry 2018-2023 Table North America Metabolic Disorders Drugs Sales by Countries (2013-2017) Table North America Metabolic Disorders Drugs Sales Share by Countries (2013-2017) Table North America Metabolic Disorders Drugs Revenue by Countries (2013-2017) Table North America Metabolic Disorders Drugs Revenue Market Share by Countries (2013-2017) Table North America Metabolic Disorders Drugs Sales by Type (2013-2017) Table North America Metabolic Disorders Drugs Sales Share by Type (2013-2017) Table North America Metabolic Disorders Drugs Revenue by Type (2013-2017) Table North America Metabolic Disorders Drugs Revenue Share by Type (2013-2017) Table North America Metabolic Disorders Drugs Sales by Downstream Industry (2013-2017) Table North America Metabolic Disorders Drugs Sales Share by Downstream Industry (2013-2017) Table Europe Metabolic Disorders Drugs Sales by Countries (2013-2017) Table Europe Metabolic Disorders Drugs Sales Share by Countries (2013-2017) Table Europe Metabolic Disorders Drugs Revenue by Countries (2013-2017) Table Europe Metabolic Disorders Drugs Revenue Market Share by Countries (2013-2017) Table Europe Metabolic Disorders Drugs Sales by Type (2013-2017) Table Europe Metabolic Disorders Drugs Sales Share by Type (2013-2017) Table Europe Metabolic Disorders Drugs Revenue by Type (2013-2017) Table Europe Metabolic Disorders Drugs Revenue Share by Type (2013-2017) Table Europe Metabolic Disorders Drugs Sales by Downstream Industry (2013-2017) Table Europe Metabolic Disorders Drugs Sales Share by Downstream Industry (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Sales by Countries (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Sales Share by Countries (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Revenue by Countries (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Revenue Market Share by Countries (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Sales by Type (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Sales Share by Type (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Revenue by Type (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Revenue Share by Type (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Sales by Downstream Industry (2013-2017) Table Asia Pacific Metabolic Disorders Drugs Sales Share by Downstream Industry (2013-2017) Table Latin America Metabolic Disorders Drugs Sales by Countries (2013-2017) Table Latin America Metabolic Disorders Drugs Sales Share by Countries (2013-2017) Table Latin America Metabolic Disorders Drugs Revenue by Countries (2013-2017) Table Latin America Metabolic Disorders Drugs Revenue Market Share by Countries (2013-2017) Table Latin America Metabolic Disorders Drugs Sales by Type (2013-2017) Table Latin America Metabolic Disorders Drugs Sales Share by Type (2013-2017) Table Latin America Metabolic Disorders Drugs Revenue by Type (2013-2017) Table Latin America Metabolic Disorders Drugs Revenue Share by Type (2013-2017) Table Latin America Metabolic Disorders Drugs Sales by Downstream Industry (2013-2017) Table Latin America Metabolic Disorders Drugs Sales Share by Downstream Industry (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Sales by Regions (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Sales Share by Regions (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Revenue by Regions (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Revenue Market Share by Regions (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Sales by Type (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Sales Share by Type (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Revenue by Type (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Revenue Share by Type (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Sales by Downstream Industry (2013-2017) Table Middle East and Africa Metabolic Disorders Drugs Sales Share by Downstream Industry (2013-2017) Table Production Volume of Metabolic Disorders Drugs by Major Manufacturers 2013-2017 Table Production Value of Metabolic Disorders Drugs by Major Manufacturers 2013-2017 Table Headquarters Location and Established Time of Metabolic Disorders Drugs Major Manufacturer Table Employees and Revenue Level of Metabolic Disorders Drugs Major Manufacturer Table Representative Metabolic Disorders Drugs Product One of Zealand Pharma Table Representative Metabolic Disorders Drugs Product Two of Zealand Pharma Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Zealand Pharma 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Rhythm Table Representative Metabolic Disorders Drugs Product Two of Rhythm Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Rhythm 2013-2017 Table Representative Metabolic Disorders Drugs Product One of OxThera Table Representative Metabolic Disorders Drugs Product Two of OxThera Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of OxThera 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Biophytis Table Representative Metabolic Disorders Drugs Product Two of Biophytis Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Biophytis 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Biophytis Table Representative Metabolic Disorders Drugs Product Two of Biophytis Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Biophytis 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Zafgen Table Representative Metabolic Disorders Drugs Product Two of Zafgen Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Zafgen 2013-2017 Table Representative Metabolic Disorders Drugs Product One of PerkinElmer Table Representative Metabolic Disorders Drugs Product Two of PerkinElmer Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of PerkinElmer 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Eternygen Table Representative Metabolic Disorders Drugs Product Two of Eternygen Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Eternygen 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Pronutria Biosciences Table Representative Metabolic Disorders Drugs Product Two of Pronutria Biosciences Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Pronutria Biosciences 2013-2017 Table Representative Metabolic Disorders Drugs Product One of MedGenome Table Representative Metabolic Disorders Drugs Product Two of MedGenome Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of MedGenome 2013-2017 Table Representative Metabolic Disorders Drugs Product One of CellCentric Table Representative Metabolic Disorders Drugs Product Two of CellCentric Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of CellCentric 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Nimbus Therapeutics Table Representative Metabolic Disorders Drugs Product Two of Nimbus Therapeutics Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Nimbus Therapeutics 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Mitobridge Table Representative Metabolic Disorders Drugs Product Two of Mitobridge Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Mitobridge 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Exelixis, Inc. Table Representative Metabolic Disorders Drugs Product Two of Exelixis, Inc. Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Exelixis, Inc. 2013-2017 Table Representative Metabolic Disorders Drugs Product One of Outpost Medicine Table Representative Metabolic Disorders Drugs Product Two of Outpost Medicine Table Metabolic Disorders Drugs Sales, Revenue, Price and Gross Margin of Outpost Medicine 2013-2017